Publications
Read about our recent research in scientific journals
The Lambert Initiative are leaders in the field of medicinal cannabinoids. Our work is regularly cited in peer-reviewed publications in scientific literature.
Journal Publications
- Bawa Z, McCartney D, Manocha R, McGregor IS (2022). Knowledge, experiences, and attitudes of Australian General Practitioners towards medicinal cannabis: a 2021-2022 survey. BMC Primary Care. 23;330.
- Lavender I, McGregor IS, Suraev AS, Grunstein RR, Hoyos CM (2023). Response to Joshi et al. Chest. Feb;163(2):e105-e106.
- Anderson LL, Bahceci D, Hawkins NA, Everett-Morgan D, Banister SD, Kearney JA, Arnold JC (2023). Heterozygous deletion of Gpr55 does not affect a hyperthermia-induced seizure, spontaneous seizures or survival in the Scn1a+/- mouse model of Dravet syndrome. PLoS One. Jan 26;18(1):e0280842.
- Anderson LL, Everett-Morgan D, Petkova SP, Silverman JL, Arnold JC (2023). Ictal vocalisations in the Scn1a+/- mouse model of Dravet syndrome. Epilepsia Open. Online ahead of print.
- McCartney D, Suraev AS, McGregor IS (2023). ‘Next-day’ effects of Δ9- tetrahydrocannabinol on cognitive function and safety-sensitive tasks: A systematic review. Cannabis and Cannabinoid Research. Feb;8(1):92-114.
- McCartney DM, Kevin RC, Suraev AS, Sahinovic A, Doohan PT, Bedoya-Perez M, Grunstien R, Hoyos C, McGregor IS (2023). How long does a single, oral dose of cannabidiol persist in plasma? Findings from three recent clinical trials. Drug Testing and Analysis. Mar;15(3):334-344.
- Milligan CJ, Anderson LL, McGregor, IS, Arnold JC, Petrou S (2023). Beyond CBD: inhibitory effects of lesser studied phytocannabinoids on human voltage-gated sodium channels. Frontiers in Physiology. Feb 20;14:1081186.
- Scicluna R, Arnold JC, McGregor IS, Bowen MT (2022). Cannabidiol reduces the severity of gastrointestinal and somatic symptoms of opioid withdrawal in male and female mice. Cannabis and Cannabinoid Research. Online ahead of print.
- Yau GTY, Tai W, Arnold JC, Chan HK, Kwok PCL (2023). Cananbidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration. Pharmaceutical Research. Online ahead of print.
- Arnold JC, McCartney DM , Suraev AS, McGregor IS (2022). The Safety and Efficacy of Low Oral Doses of Cannabidiol: An Evaluation of the Evidence. Clinical And Translational Science.
- Bahceci D, Anderson LL, Kevin RC, Doohan PT, Arnold JC (2022). Hyperthermia-Induced Seizures Enhance Brain Concentrations of the Endocannabinoid-Related Linoleoyl Glycerols in a Scn1a+/- Mouse Model of Dravet Syndrome. Cannabis and Cannabinoid Research.
- Bawa Z, Saini B, McCartney DM, Bedoya-Perez M, McLachlan A, McGregor IS (2022). A Cross-Sectional Survey Exploring the Knowledge, Experiences, and Attitudes of Australian Community Pharmacists Towards Medicinal Cannabis. International Journal of Clinical Pharmacy.
- Hutten NRPW, Arkell TR, Vinckenbosch F, Schepers EL, Kevin R, Theunissen EL, Kuypers KPC, McGregor IS, Ramaekers JG (2022). Cannabis containing equivalent concentrations of delta-9- tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC- dominant cannabis. Psychopharmacology. 239; 731–3741.
- Kevin RC, Cairns EA, Arnold JC, Bowen MB, McGregor IS, Banister SC (under review). Off- Target Pharmacological Profiling of Synthetic Cannabinoid Receptor Agonists including AMB- FUBINACA, CUMYL-PINACA, PB-22, and XLR-11. Frontiers in Psychiatry.
- Mills L, Dunlop A, Montebello M, Copeland J, Bruno R, Jefferies M, McGregor IS, Lintzeris N (2022). Correlates of treatment engagement and client outcomes: Results of a randomised controlled trial of nabiximols for the treatment of cannabis dependence. Substance Abuse Treatment, Prevention, and Policy.
- Sparkes E, Boyd R, … Markham JW … McGregor IS … Cairns EA … Ametovski A, Banister SD (2022). Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA, MDMB-4F-BUTINACA and their analogs. Frontiers in Psychiatry. 13:1010501.
- Udoh M, Bladen C, Heblinski M, Luo JL, Janve VS, Anderson LL, McGregor IS, Arnold JC (2022). The anticonvulsant phytocannabinoids CBGVA and CBDVA inhibit recombinant T-type channels. Frontiers in Pharmacology. Nov 1;13:1048259.
- Colvin EK, Hudson AL, Anderson LL, Kumar RP, McGregor IS, Howell VM, & Arnold JC (2022). An Examination of the Anti-Cancer Properties of Plant Cannabinoids in Preclinical Models of Mesothelioma. Cancers (Basel) 14. (virtual cover paper).
- Barrie N, Manolios N, Stuart J, Chew T, Arnold J, Sadsad R, De Campo L, Knott RB, White J, Booth D, Ali M, & Moghaddam MJ (2022). Design and function of targeted endocannabinoid nanoparticles. Scientific Reports; 12: 17260.
- Sparkes E, Boyd R, Chen S, Markham JW, Luo JL, Goyzun T, Zaman H, Fletcher C, Ellison R, McGregor IS, Santiago MJ, Lai F, Gerona RR, Connor M, Hibbs DE, Cairns EA, Glass M, Ametovski A, Banister SD (2022). Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA, MDMB-4F-BUTINACA and their analogs. Frontiers in Psychiatry.
- Colvin EK, Hudson AL, Anderson LL, Kumar RP, McGregor IS, Howell VM & Arnold JC (2022). An examination of the anti-cancer properties of plant cannabinoids in preclinical models of mesothelioma. Cancers. 14(15): 3813
- Lintzeris N, Mills L, Abelev SV, Suaraev A, Arnold JC & McGregor IS (2022). Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20). Harm Reduction Journal. 19, 88.
- Berger M, LI M, Rice S, Davey CG, Ratheesh A, Adams S, Jackson H, Hetrick S, Parker A, Spelman T, Kevin R, McGregor IS, McGorry P, & Amminger P (2022). Cannabidiol for treatment resistant anxiety disorders in young people: an open-label trial. Journal of Clinical Psychiatry. 83(5):21m14130
- Berger M, Amminger GP & McGregor IS (2022). Medicinal cannabis for the treatment of anxiety disorders. Australian Journal of General Practice. August 2022.
- Anderson LL, Arnold JC, McGregor IS & Nation TR (2022). A Potential Drug-Gene-Drug Interaction Between Cannabidiol, CYP2D6*4, and Fluoxetine: A Case Report. Journal of Clinical Psychopharmacology. 42(4): 422-424
- Milligan C, Anderson L, Bowen M, McGregor IS, Arnold JC, & Petrou S (2022). A nutraceutical product, extracted from Cannabis sativa, modulates voltage-gated sodium channel function. Journal of Cannabis Research. 4: 30
- Lavender I, McGregor IS, Suraev A, Grunstein RR, & Hoyos CM (2022). Cannabinoids, insomnia, and other sleep disorders. Chest. Online ahead of print.
- MacPhail SL, Bedoya-Pérez MA, Cohen R, Kotsirilos V, McGregor IS, and Cairns EA (2022). Medicinal cannabis prescribing in Australia: An analysis of trends over the first five years. Frontiers in Pharmacology. 13: 885655.
- Kevin RC, Mirlohi S, Manning J, Boyd R, Cairns EA, Sparkes EA, Ametovski A, Luo JL, Jorgensen W, Ellison R, Gerona RR, McGregor IS, Glass M, Connor M, Bladen C, Zamponi GW, Banister SD (2022). Putative synthetic cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and their analogues are cannabinoid receptor (CB1 and CB2) agonists and T-type calcium channel (CaV3) inhibitors. ACS Chemical Neuroscience. 4;13(9):1395-1409
- Markham J, Sparkes E, Boyd R, Chen S, Manning JJ, Finlay D, Lai F, McGregor E, Maloney CJ, Gerona RR, Connor M, McGregor IS, Hibbs DE, Glass M, Kevin RC, & Banister SD (2022). Defining steric requirements at CB1 and CB2 cannabinoid receptors using synthetic cannabinoid receptor agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and their analogues. ACS Chemical Neuroscience. 13: 1281–1295.
- McCartney D, Arkell TR, Irwin C, & McGregor IS (2022). Response to: “Cannabis use before safety sensitive work: What delay is prudent?” Neuroscience & Biobehavioural Reviews. 137: 104684.
- McCartney D, Suraev AS, Doohan PT, Irwin C, Kevin RC, Grunstein RR, Hoyos CM, & McGregor IS (2022). Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial. Human Psychopharmacology: Clinical & Experimental. Sep;35(5):e2749
- Umpierrez LS, Costa PA, Michelutti EA, Baracz SJ, Sauer M, Turner AJ, Everett NA, Arnold JC, McGregor IS & Cornish JL (2022). Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses. Psychopharmacology (Berl.) 239: 1593–1603.
- Anderson LL, Udoh M, Everett-Morgan D, Heblinski M, McGregor IS, Banister SD, & Arnold, JC (2022). Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. J Cannabis Res 4: 2.
- Suraev A, Benson MJ, Martin L, Lintzeris N, & McGregor IS (2021). Determination of contaminants in artisanal cannabis products used for childhood epilepsy in the Australian community: A sub-analysis of the 'PELICAN' study. Epilepsy & behavior : E&B 127: 108496.
- Arkell TR, Kevin RC, Vinckenbosch F, Lintzeris N, Theunissen E, Ramaekers JG, & Mcgregor IS (2021). Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials. Addiction Biology n/a: e13125.
- Anderson LL, Doohan PT, Hawkins NA, Bahceci D, Thakur GA, Kearney JA, & Arnold JC. (2021). The endocannabinoid system impacts seizures in a mouse model of Dravet syndrome. Neuropharmacology: 108897.
- McCartney D, Arkell TR, Irwin C, Kevin RC, & McGregor IS (2021). Are blood and oral fluid Δ9-tetrahydrocannabinol (THC) and metabolite concentrations related to impairment? A meta-regression analysis. Neuroscience & Biobehavioral Reviews.
- Sparkes E, Cairns EA, Kevin RC, Lai F, Grafinger K, Chen S, Deventer M, Ellison R, Boyd R, Martin L, Mcgregor IS, Gerona R, Hibbs D, Auwaerter V, Glass M, Stove C, & Banister SD (2021). Structure-activity relationships of valine-, tert-leucine-, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. RSC Medicinal Chemistry.
- Ametovski A, Cairns EA, Grafinger KE, Cannaert A, Deventer MH, Chen S, Wu X, Shepperson CE, Lai F, Ellison R, Gerona R, Blakey K, Kevin R, Mcgregor IS, Hibbs DE, Glass M, Stove C, Auwärter V, & Banister SD (2021). NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity? ACS Chemical Neuroscience.
- Anderson LL, Heblinski M, Absalom NL, Hawkins NA, Bowen MT, Benson MJ, Zhang F, Bahceci D, Doohan PT, Chebib M, Mcgregor IS, Kearney JA, & Arnold JC (2021). Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. British Journal of Pharmacology n/a.
- Henderson L, Kotsirilos V, Cairns EA, Ramachandran A, Peck C, & McGregor IS (2021). Medicinal cannabis in the treatment of chronic pain. Australian Journal for General Practitioners 50: 724-732.
- McCartney D, Kevin RC, Suraev AS, Irwin C, Grunstein RR, Hoyos CM, & Mcgregor IS (2021). Orally administered cannabidiol does not produce false-positive tests for Δ9-tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000. Drug testing and analysis.
- Darke S, Banister S, Farrell M, Duflou J, & Lappin J (2021). ‘Synthetic cannabis’: A dangerous misnomer. International Journal of Drug Policy 98: 103396.
- Jackson MA, Brown AL, Johnston J, Clancy R, McGregor IS, Bruno R, Lintzeris N, Montebello M, Luksza J, Bowman J, Phung N, Allsop D & Dunlop AJ (2021). The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients. Journal of Cannabis Research 3: 33.
- Anderson LL, Etchart MG, Bahceci D, Golembiewski TA, & Arnold JC (2021). Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations. Scientific Reports 11: 14948.
- Amminger GP, Lin A, Kerr M, Weller A, Spark J, Pugh C, O'Callaghan S, Berger M, Clark SR, Scott JG, Baker A, McGregor IS, Cotter D, Sarnyai Z, Thompson A, Yung AR, O'Donoghue B, Killackey E, Mihalopoulos C, Yuen HP, Nelson B, & McGorry PD (2021). Cannabidiol for at risk for psychosis youth: A randomized controlled trial. Early Intervention in Psychiatry. Epub ahead of print.
- Zhou C, Assareh N, & Arnold JC (2021). The Cannabis Constituent Cannabigerol Does Not Disrupt Fear Memory Processes or Stress-Induced Anxiety in Mice. Cannabis Cannabinoid Res.
- Doohan PT, Oldfield LD, Arnold JC, & Anderson LL (2021). Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization. The AAPS journal 23: 91.
- Rodan SC, Aouad P, McGregor IS, & Maguire S (2021). Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa. OBM Neurobiology 2021;5(2):28;
- Anderson LL, Doohan PT, Oldfield L, Kevin RC, Arnold JC, Berger M, Amminger GP, & Mcgregor IS (2021). Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. Journal of clinical psychopharmacology
- Perkins D, Brophy H, McGregor IS, O'Brien P, Quilter J, McNamara L, Sarris J, Stevenson M, Gleeson P, Sinclair J & Dietze P (2021). Medicinal cannabis and driving: the intersection of health and road safety policy. International Journal of Drug Policy 97: 103307.
- Arkell TR, McCartney D, & McGregor IS (2021). Medical cannabis and driving. Australian Journal for General Practitioners 50: 357-362.
- Arnold JC (2021). A primer on medicinal cannabis safety and potential adverse effects. Australian Journal for General Practitioners 50: 345-350.
- Satpute Janve V, Anderson LL, Bahceci D, Hawkins NA, Kearney JA, & Arnold JC (2021). The Heat Sensing Trpv1 Receptor Is Not a Viable Anticonvulsant Drug Target in the Scn1a+/− Mouse Model of Dravet Syndrome. Frontiers in pharmacology 12.
- Grafinger KE, Vandeputte MM, Cannaert A, Ametovski A, Sparkes E, Cairns E, Juchli PO, Haschimi B, Pulver B, Banister SD, Stove CP, & Auwärter V (2021). Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays PART III: The G protein pathway and critical comparison of different assays. Drug testing and analysis. 13(7): 1412-1429.
- Martin LJ, Cairns EA, Heblinski M, Fletcher C, Krycer JR, Arnold JC, McGregor IS, Bowen MT, & Anderson LL (2021). Cannabichromene and Δ9-Tetrahydrocannabinolic Acid Identified as Lactate Dehydrogenase-A Inhibitors by in Silico and in Vitro Screening. Journal of Natural Products.
- Pike E, Grafinger KE, Cannaert A, Ametovski A, Luo JL, Sparkes E, Cairns EA, Ellison R, Gerona R, Stove CP, Auwärter V & Banister SD (2021). Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays PART I: Synthesis, analytical characterization, and binding affinity for human CB1 receptors. Drug testing and analysis 13(7): 1383-1401.
- Ramaekers JG, Arkell TR, & McGregor IS (2021). Driving Impairment Following Vaporization of Cannabis-Reply. JAMA 325: 1226-1227.
- Grafinger KE, Cannaert A, Ametovski A, Sparkes E, Cairns E, Banister SD, Auwärter V & Stove CP (2021). Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA and MMB-4CN-BUTINACA using a combination of binding and different CB(1) receptor activation assays PART II: Structure activity relationship assessment via a β-arrestin recruitment assay. Drug testing and analysis.
- Vo SV, Banister SD, Freelander I, Werry EL, Reekie TA, Ittner LM, & Kassiou M (2020). Reversing binding sensitivity to A147T translocator protein. RSC medicinal chemistry 11: 511-517.
- Martin LJ, Banister SD, & Bowen MT (2021). Understanding the complex pharmacology of cannabidiol: mounting evidence suggests a common binding site with cholesterol. Pharmacological Research: 105508.
- Bladen C, Mirlohi S, Santiago M, Longworth M, Kassiou M, Banister SD, & Connor M (2021). Modulation of human T-type calcium channels by synthetic cannabinoid receptor agonists in vitro. Neuropharmacology 187: 108478.
- McCartney D, Arkell TR, Irwin C, & McGregor IS (2021). Determining the magnitude and duration of acute Δ(9)-tetrahydrocannabinol (Δ(9)-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review. Neuroscience and biobehavioral reviews 126:175-193.
- Arkell TR, Spindle TR, Kevin RC, Vandrey R, & McGregor IS (2021). The failings of per se limits to detect cannabis-induced driving impairment: Results from a simulated driving study. Traffic Injury Prevention: 1-6.
- Anderson LL, Ametovski A, Lin Luo J, Everett-Morgan D, McGregor IS, Banister SD, & Arnold JC (2021). Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome. ACS Chemical Neuroscience 12(2):330-339.
- Arkell TR, Vinckenbosch F, Kevin R, Theunissen EL, McGregor IS & Ramaekers JG (2020). Effect of cannabidiol and delta-9-tetrahydrocannabinol on driving performance: a randomized clinical trial. JAMA 324: 2177-2186.
- Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, Ellison R, Gerona R, Banister SD & Stove CP (2020). Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA. ACS Chemical Neuroscience 11: 4434-4446.
- Absalom NL, Liao VWY, Kothur K, Indurthi DC, Bennetts B, Troedson C, Mohammad SS, Gupta S, McGregor IS, Bowen MT, Lederer D, Mary S, De Waele L, Jansen K, Gill D, Kurian MA, McTague A, Møller RS, Ahring PK, Dale RC & Chebib M (2020). Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies. Brain Communications 2. Video abstract.
- Kevin RC, Vogel R, Doohan P, Berger M, Amminger GP & McGregor IS (2020). A validated method for the simultaneous quantification of CBD, THC, and their metabolites in human plasma, and application to plasma samples from an oral CBD open label trial. Drug Testing and Analysis. Epub ahead of print.
- McCartney D, Isik AD, Rooney K, Arnold JC, Bartlett DJ, Murnion B & McGregor IS (2020). The effect of daily aerobic cycling exercise on sleep quality during inpatient cannabis withdrawal: A randomised controlled trial. Journal of Sleep Research: e13211.
- Ametovski A, Macdonald C, Manning JJ, Haneef SAS, Santiago M, Martin L, Sparkes E, Reckers A, Gerona RR, Connor M, Glass M & Banister SD (2020). Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA. ACS Chemical Neuroscience 11: 3672-3682.
- Arkell TR, Lintzeris N, Mills L, Suraev A, Arnold JC & McGregor IS (2020). Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 Survey. Accident; Analysis and Prevention 148: 105784.
- Anderson LL, Etchart MG, MacNair L, Land MH, Mosesova IA, Bonn-Miller MO & Arnold JC. (2020). In Vitro Screening of Three Commercial Cannabis-Based Products on ATP-Binding Cassette and Solute-Carrier Transporter Function. Cannabis and Cannabinoid Research. Epub ahead of print.
- Arnold JC, Nation T & McGregor IS (2020). Prescribing medicinal cannabis. Australian Prescriber 43: 152-159.
- Benson MJ, Anderson LL, Low IK, Luo JL, Kevin RC, Zhou C, McGregor IS & Arnold JC (2020). Evaluation of the Possible Anticonvulsant Effect of Δ9-Tetrahydrocannabinolic Acid in Murine Seizure Models. Cannabis and Cannabinoid Research. Epub ahead of print.
- McGregor IS, Cairns EA, Abelev S, Cohen R, Henderson M, Couch D, Arnold JC & Gauld N (2020). Access to cannabidiol without a prescription: A cross-country comparison and analysis. International Journal of Drug Policy 85: 102935.
- McGregor IS &Arnold JC (2020) A Submission to the Advisory Committee on Medicines and Scheduling on the Down-Scheduling of Low Dose Cannabidiol. Published at Public submissions on scheduling matters.
- Grimison P, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber P, Haber P, Olver I, Walsh A, Mcgregor I, Cheung Y, Tognela A, Hahn C, Briscoe K, Aghmesheh M, Fox P, Abdi E, Clarke S, Della-Fiorentina S, Shannon J, Gedye C, Begbie S, Simes J & Stockler M (2020). Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting (CINV): a randomised, placebo-controlled, phase 2 crossover trial. Annals of Oncology : official journal of the European Society for Medical Oncology 31: 1553-1560.
- Lintzeris N, Mills L, Dunlop A, Copeland J, McGregor I, Bruno R, Kirby A, Montebello M, Hall M, Jefferies M, Kevin R & Bhardwaj A (2020). Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. Drug and Alcohol Dependence 215: 108220.
- McCartney D, Benson MJ, Desbrow B, Irwin C, Suraev A & McGregor IS (2020). Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research. Sports Medicine - Open 6: 27.
- McCartney D, Benson MJ, Suraev AS, Irwin C, Arkell TR, Grunstein RR, et al. (2020). The effect of cannabidiol on simulated car driving performance: A randomised, double-blind, placebo-controlled, crossover, dose-ranging clinical trial protocol. Human Psychopharmacology: e2749.
- Monte AA, Hopkinson A, Saben J, Shelton SK, Thornton S, Schneir A, Pomerleau A, Hendrickson R, Arens A, Cole J, Chenoweth J, Martin S, Adams A, Banister SD & Gerona R (2020). The Psychoactive Surveillance Consortium and Analysis Network (PSCAN): the first year. Addiction (Abingdon, England) 115: 270-278.
- Ong RS, Kappatos DC, Russell SGG, Poulsen HA, Banister SD, Gerona RR, Glass M, Johnson CS & Mccarthy MJ (2020). Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines, and cannabinoids in human whole blood by liquid chromatography-tandem mass spectrometry - A New Zealand perspective of use in 2018. Drug Testing and Analysis 12: 195-214.
- Anderson LL, Low IK, McGregor IS & Arnold JC (2020). Interactions between cannabidiol and Δ(9) -tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome. British Journal of Pharmacology 177: 4261-4274.
- Benson MJ, Abelev SV, Corte CJ, Connor SJ & McGregor IS (2020). Attitudes and Knowledge of Australian Gastroenterologists Around the Use of Medicinal Cannabis for Inflammatory Bowel Disease. Crohn's & Colitis 360 2.
- Lintzeris N, Mills L, Suraev A, Bravo M, Arkell T, Arnold JC, Benson MJ & McGregor IS (2020). Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduction Journal 17: 37.
- Assareh N, Gururajan A, Zhou C, Luo JL, Kevin RC & Arnold JC (2020). Cannabidiol disrupts conditioned fear expression and cannabidiolic acid reduces trauma-induced anxiety-related behaviour in mice. Behavioural Pharmacology 31: 591-596.
- Suraev A, Grunstein RR, Marshall NS, D'Rozario AL, Gordon CJ, Bartlett DJ, Wong K, Yee BY, Vandrey R, Irwin C, Arnold JC, McGregor IS & Hoyos CM (2020). Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder ('CANSLEEP' trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. BMJ Open 10: e034421.
- Suraev AS, Marshall NS, Vandrey R, McCartney D, Benson MJ, McGregor IS, Grunstein RR & Hoyos CM (2020). Cannabinoid therapies in the management of sleep disorders: a systematic review of preclinical and clinical studies. Sleep Medicine Reviews: 101339.
- Benson MJ, Abelev SV, Connor SJ, Corte CJ, Martin LJ, Gold LK, Suraev AS & McGregor IS (2020). Medicinal Cannabis for Inflammatory Bowel Disease: A Survey of Perspectives, Experiences, and Current Use in Australian Patients. Crohn's & Colitis 360 2.
- Gamage TF, Barrus DG, Kevin RC, Finlay DB, Lefever TW, Patel PR, Grabenauer M, Glass M, McGregor IS & Thomas B (2020). In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018. Pharmacology, Biochemistry, and Behavior 193: 172918.
- Patel M, Manning JJ, Finlay DB, Javitch JA, Banister SD, Grimsey NL & Glass M (2020). Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. Biochemical Pharmacology 175: 113871.
- Heblinski M, Santiago M, Fletcher C, Stuart J, Connor M, McGregor IS, et al. (2020). Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Actions of Phytocannabinoids or Endocannabinoids on TRPA1 and TRPV1 Channels. Cannabis and Cannabinoid Research 5: 305-317.
- Bahceci D, Anderson LL, Occelli Hanbury Brown CV, Zhou C & Arnold JC (2020). Adolescent behavioral abnormalities in a Scn1a+/− mouse model of Dravet syndrome. Epilepsy & Behavior : E&B 103: 106842.
- Sachdev S, Banister SD, Santiago M, Bladen C, Kassiou M & Connor M (2020). Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists. Pharmacology Research & Perspectives 8: e00566.
- Wouters E, Walraed J, Banister SD & Stove CP (2019). Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists. Biochemical Pharmacology 169: 113623.
- Finlay DB, Manning JJ, Ibsen MS, Macdonald CE, Patel M, Javitch JA, Banister SD & Glass M (2019). Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA. ACS Chemical Neuroscience 10: 4350-4360.
- Anderson LL, Low IK, Banister SD, McGregor IS, & Arnold JC (2019). Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome. Journal of natural products 82: 3047-3055.
- Wouters E, Walraed J, Banister S, & Stove C (2019). Insights into biased signalling at cannabinoid receptors: synthetic cannabinoid receptor agonists. Biochemical Pharmacology 169: 113623
- Anderson LL, Absalom NL, Abelev SV, Low IK, Doohan PT, Martin LJ, et al. (2019). Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia 60: 2224–2234.
- Santiago M, Sachdev S, Arnold JC, McGregor IS, & Connor M (2019). Absence of entourage: Terpenoids commonly found in Cannabis sativa do not modulate the functional activity of Δ9-THC at human CB1 and CB2 receptors. Cannabis and cannabinoid research 4: 165-176.
- Udoh M, Santiago M, Devenish S, McGregor IS, & Connor M (2019). Cannabichromene is a cannabinoid CB2 receptor agonist. British Journal of Pharmacology 176: 4537-4547.
- Smith K, Kassem M, Clarke D, Kuligowski M, Bedoya-Perez M, Todd S, et al. (2019). Microglial cell hyper-ramification and neuronal dendritic spine loss in the hippocampus and medial prefrontal cortex in a mouse model of PTSD. Brain, Behavior, and Immunity 80: 889-899
- Arkell TR, Kevin RC, Stuart J, Lintzeris N, Haber PS, Ramaekers JG, et al. (2019). Detection of Δ9 THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devices. Drug Testing and Analysis 11: 1486-1497.
- Lintzeris N, Bhardwaj A, Mills L, Dunlop A, Copeland, J McGregor IS, et al. (2019). Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial. JAMA Internal Medicine 179: 1242–1253
- Arkell TR, Lintzeris N, Kevin RC, Ramaekers JG, Vandrey R, Irwin C, & McGregor IS (2019). Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology (Berl) 236: 2713-2724
- Kevin RC, Anderson L, McGregor IS, Boyd R, Manning JJ, Glass M, et al. (2019) CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist, Frontiers in Pharmacology 10: 595
- Bedoya-Perez M, Smith K, Kevin R, Luo J, Crowther M, & McGregor IS (2019). Parameters That Affect Fear Responses in Rodents and How to Use Them for Management. Frontiers in Ecology and Evolution 7: 136
- Absalom NL, Ahring PK, Liao VW, Balle T, Jiang T, Anderson LL, et al. (2019). Functional genomics of epilepsy-associated mutations in the GABAA receptor subunits reveal that one mutation impairs function and two are catastrophic. Journal of Biological Chemistry 294: 6157-6171
- Banister SD, Kevin RC, Martin L, Adams A, Macdonald C, Manning JJ, et al. (2019). The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA 5F-PY-PINACA and their analogs. Drug Testing and Analysis 11: 976-989
- Gamage TF, Farquhar CE, McKinnie RJ, Kevin RC, McGregor IS, Trudell ML, et al. (2019). Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors, Journal of Pharmacology and Experimental Therapeutics 368: 414-422
- Clarke DJ, Chohan TW, Kassem MS, Smith KL, Chesworth R, Karl T, et al. (2019). Neuregulin 1 Deficiency Modulates Adolescent Stress-Induced Dendritic Spine Loss in a Brain Region-Specific Manner and Increases Complement 4 Expression in the Hippocampus. Schizophrenia Bulletin 45: 339-349
- Banister SD, Adams A, Kevin RC, Macdonald C, Glass M, Boyd R, et al. (2019). Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. Drug Testing and Analysis 11: 279-291
- Kevin RC, Kovach AL, Lefever TW, Gamage TF, Wiley JL, McGregor IS, et al. (2019). Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA 5F-CUMYL-PICA AMB-FUBINACA MDMB-FUBINACA NNEI and MN-18 during exposure to high temperatures. Forensic Toxicology 37: 17-26
- Banister SD, Arnold JC, Connor M, Glass M, & McGregor IS (2019). Dark Classics in Chemical Neuroscience: Delta(9)-Tetrahydrocannabinol. ACS Chemical Neuroscience 10: 2160-2175
- Clarke DJ, Sarkissian L, Todd SM, Suraev AS, Bahceci D, Brzozowska N, & Arnold JC (2019). Nrg1 deficiency modulates the behavioural effects of prenatal stress in mice. Progress in Neuropsychopharmacology and Biological Psychiatry 88: 86-95.
- McGregor IS (2018). Cannabis use and non-cancer chronic pain, Lancet Public Health. 3(10): 467
- Hay G, Baracz S, Everett N, Roberts J, Costa P, Arnold J, McGregor IS, Cornish J (2018) Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats, Journal of Psychopharmacology 32(12) 1369-1378
- Lovell M, Bruno R, Johnston J, Matthews A, McGregor IS, Allsop D, Lintzeris N (2018), Cognitive physical and mental health outcomes between long-term cannabis and tobacco users, Addictive Behaviors 79 178-188,
- Suraev A, Lintzeris N, Stuart J, Kevin R, Blackburn R, Richards E, Arnold J, Ireland C, Todd L, Allsop D, McGregor IS (2018), Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community, Scientific Reports 8(1) 28127
- Kevin R, Lefever T, Snyder R, Patel P, Gamage T, Fennell T, Wiley J, McGregor IS, Thomas B, (2018), Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18, Drug Testing and Analysis 10(1) 137-147
- Karanges E, Suraev A, Elias N, Manocha R, McGregor IS (2018) Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey, BMJ Open 8(7) 1-9
- Lintzeris N, Driels J, Elias N, Arnold J, McGregor IS, Allsop D, (2018) Medicinal cannabis in Australia 2016: the Cannabis as Medicine Survey (CAMS-16), Medical Journal of Australia 209(5) 211-216
- Gamage T, Farquhar C, Lefever T, Marusich J, Kevin R, McGregor IS, Wiley J, Thomas B, (2018), Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18 NNEI CUMYL-PICA and 5-Fluoro-CUMYL-PICA, Journal of Pharmacology and Experimental Therapeutics 365(2) 437-446
- Mersiades A, Tognela A, Haber P, Stockler M, Lintzeris N, Simes R, McGregor IS, Olver I, Allsop D, Gedye C, Kirby A, Morton R, Wong N, Walsh A, Grimison P et al (2018) Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). BMJ Open 8(9) 1-8
- Bhardwaj A, Allsop D, Copeland J, McGregor I, Dunlop A, Shanahan M, Bruno R, Phung N, Montebello M, Sadler C, Gugusheff J, Lintzeris N et al (2018) Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol, BMC Psychiatry 18(1) 1-14
- Banister S, Olson A, Winchester M, Stuart J, Edington A, Kevin R, Longworth M, Herrera M, Connor M, McGregor I, Kassiou M, et al (2018) The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs, Drug Testing and Analysis 10(7) 1099-1109
- Arnold, JC, Isomers of THC, in WHO Expert Committee on Drug Dependence Pre-Review 2018, World Health Organisation: Geneva, Switzerland
- Arnold, JC, Delta-9-tetrahydrocannabinol, in WHO Expert Committee on Drug Dependence Pre-Review 2018, World Health Organisation: Geneva, Switzerland
- Arnold, JC, Extracts and tinctures of cannabis, in WHO Expert Committee on Drug Dependence Pre-Review 2018, World Health Organisation Geneva, Switzerland
- Arnold, JC, Cannabis plant and cannabis resin, in WHO Expert Committee on Drug Dependence Pre-Review 2018, World Health Organisation: Geneva, Switzerland
- Kevin RC, Lefever TW, Snyder RW, Wiley JL, McGregor IS, Thomas BF. (2017) In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA, Forensic Toxicology 35: 333-347.
- Longworth M, Banister SD, Boyd R, Connor M, McGregor IS, Kassiou M. (2017) Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues, ACS Chemical Neuroscience 8(10), 2159-2167.
- Kevin RC, Lefever TW, Snyder RW, Wiley JL, McGregor IS, Thomas BF. (2017) In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA, Forensic Toxicology 35: 333-347
- Longworth M, Banister SD, Boyd R, Connor M, McGregor IS, Kassiou M. (2017) Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues, ACS Chemical Neuroscience 8(10), 2159-2167
- Bakas T, van Nieuwenhuijzen PS, Devenish SO, McGregor IS, Arnold JC, Chebib M. (2017) The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors, Pharmacological Research 119:358-370
- Suraev AS, Todd L, Bowen MT, Allsop DJ, McGregor IS, Ireland C, Lintzeris N. (2017) An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use, Epilepsy and Behavior 70: 334-340
- Kevin RC, Wood KE, Stuart J, Mitchell AJ, Moir M, Banister SD, Kassiou M and McGregor IS (2017). Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA, Journal of Psychopharmacology 31:757-769
- Kevin RC, Allsop DJ, Lintzeris N, Dunlop AJ, Booth J, McGregor IS (2017) Urinary cannabinoid levels during Nabiximols (Sativex®)-medicated inpatient cannabis withdrawal, Forensic Toxicology35(1), 33-44
- Clarke D, Stuart J, McGregor IS, Arnold J (2017). Endocannabinoid dysregulation in cognitive and stress-related brain regions in the Nrg1 mouse model of schizophrenia, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 72, 9-15
- Allsop, D., Rooney, K., Arnold, J., Bhardwaj, A., Brunu, R., Bartlett, D., Montebello, M., Arkell, T., Richards, E., Gugusheff, J., Rooke, S., Kerley, W., Murnion, B., Haber, P., McGregor, I., Lintzeris, N. (2017). Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol, Mental Health and Physical Activity, 13, 57-67
- Todd, SM, Zhou, C, Clarke, DJ, Chohan, TW, Bahceci, D, and Arnold, JC, Interactions between cannabidiol and Delta9-THC following acute and repeated dosing: Rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway, European Neuropsychopharmacology, 2017; 27(2): 132-145.
- Silveira, MM, Arnold, JC, Laviolette, SR, Hillard, CJ, Celorrio, M, Aymerich, MS, and Adams, WK, Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks, Neuroscience and Biobehavioral Review, 2017; 76(Pt B): 380-395.
- Brzozowska, NI, Smith, KL, Zhou, C, Waters, PM, Cavalcante, LM, Abelev, SV, Kuligowski, M, Clarke, DJ, Todd, SM, and Arnold, JC, Genetic deletion of P-glycoprotein alters stress responsivity and increases depression-like behavior, social withdrawal and microglial activation in the hippocampus of female mice, Brain Behaviour and Immunity, 2017; 65: 251-261.
- Brzozowska, NI, de Tonnerre, EJ, Li, KM, Wang, XS, Boucher, AA, Callaghan, PD, Kuligowski, M, Wong, A, and Arnold, JC, The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions, Neuropsychopharmacology, 2017; 42(11): 2222-2231.
- Bennett, MR, Arnold, J, Hatton, SN, and Lagopoulos, J, Regulation of fear extinction by long-term depression: The roles of endocannabinoids and brain derived neurotrophic factor. Behavioural Brain Research, 2017; 319: 148-164.
- Arnold, J., Allsop, D., Lintzeris, N., McGregor, I. (2016). Evidence Check: Pharmacological actions and associated therapeutic levels of phytocannabinoids, (pp. 1 - 81). Sydney, Australia: The Sax Institute (print only)
- Luckett T, Phillips J, Lintzeris N, Allsop D, Lee J, Solowij N, Martin J, Lam L, Aggarwal R, McCaffrey N, Currow D, Chye R, Lovell M, McGregor IS, Agar M (2016) Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: A survey of preferences, attitudes and beliefs among patients willing to consider participation, Internal Medicine Journal 46(11), 1269-1275
- Brzozowska N, Li KM, Wang XS, Booth J, Stuart J, McGregor IS, Arnold JC (2016) ABC transporters P-GPand BCRP do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. PeerJ 4: e2081
- Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, Mack JB, Glass M, McGregor IS, Connor M, Kassiou M (2016) Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues, ACS Chemical Neuroscience 7: 1241-54
- Arnold, JC, Allsop, D, Lintzeris, N, and McGregor, IS, Pharmacological actions and associated therapeutic levels of phytocannabinoids: an evidence check review brokered by the Sax Institute for the NSW Ministry of Health, 2016, Sax Institute: Sydney, Australia.
- Todd, SM and Arnold, JC, Neural correlates of interactions between cannabidiol and Delta(9) -tetrahydrocannabinol in mice: implications for medical cannabis, British Journal of Pharmacology, 2016; 173(1): 53-65.
- Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Beinat C, Wilkinson SM, Glass M, Connor M, McGregor IS, Kassiou M (2015). The pharmacology of indole and indazole cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 6, 1546-1559
- Banister SD, Stuart J, Conroy T, Longworth M, Manohar M, Beinat C, Wilkinson SM, Kevin RC, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M (2015). Structure-activity relationships (SARs) of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4-homologues. Forensic Toxicology, 1-12
- Allsop D, Bartlett D, Johnston J, Helliwell D, Winstock A, McGregor IS, Lintzeris N (2015). The effects of lithium carbonate supplemented with nitrazepam on sleep disturbance during cannabis abstinence. Journal of Clinical Sleep Medicine, 11, 1153-1162
- Banister S, Stuart J, Kevin R, Edington A, Longworth M, Wilkinson S, Beinat C, Buchanan A, Hibbs, D, Glass M, Connor M, McGregor IS, Kassiou M (2015). The effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience 6:1445-1458
- Allsop D, Lintzeris N, Copeland J, Dunlop A, McGregor IS (2015). Cannabinoid Replacement Therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal and dependence, Clinical Pharmacology & Therapeutics 97: 571-574
- Arnold, JC, Report on the medical applications of cannabis and the cannabinoids, for the Legislative Assembly of the Australian Capital Territory, Editor 2015. p. 1-32
Related articles
